Skip Navigation

Annals of Oncology 2009 20(3):397; doi:10.1093/annonc/mdp042
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Pulmonary function in patients with breast cancer receiving dose-dense chemotherapy
 
After showing an improvement in survival, dose-dense doxorubicin–cyclophosphamide followed by a taxane has been widely used, especially for patients with node-positive breast cancer, with a beneficial effect on survival. Although dose-dense chemotherapy (DDC) is generally well tolerated, some women develop significant dyspnea that persists after treatment completion. Examination of these patients to identify possible causes, such as anemia, cardiovascular disease, and pulmonary injury, has disclosed that . . . [Full Text of this Article]


   Gabapentin in the management of hot flashes in men
 

   Bortezomib in patients with relapsed or refractory mantle cell lymphoma
 

   The causes of cancer in France
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
R. Yerushalmi, M. R. Kramer, S. Rizel, A. Sulkes, K. Gelmon, T. Granot, V. Neiman, and S. M. Stemmer
Ann Oncol 2009 20: 437-440. [Abstract] [Full Text]  

A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)
C. L. Loprinzi, A. C. Dueck, B. S. Khoyratty, D. L. Barton, S. Jafar, K. M. Rowland, Jr, P. J. Atherton, G. W. Marsa, W. H. Knutson, J. D. Bearden, III, L. Kottschade, and T. R. Fitch
Ann Oncol 2009 20: 542-549. [Abstract] [Full Text]  

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, S. Nasta, O. A. O'Connor, H. Shi, A. L. Boral, and R. I. Fisher
Ann Oncol 2009 20: 520-525. [Abstract] [Full Text]  

The causes of cancer in France
P. Boffetta, M. Tubiana, C. Hill, M. Boniol, A. Aurengo, R. Masse, A.-J. Valleron, R. Monier, G. de Thé, P. Boyle, and P. Autier
Ann Oncol 2009 20: 550-555. [Abstract] [Full Text]